AP-101

DB17947InvestigationalProtein Based Therapies

AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.

Mechanism: Pharmacologically active on Superoxide dismutase [Cu-Zn]
Curator reviewed
Code names: AP-101

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with AP-101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.